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Background: Nine-beta-D-arabinofuranosylguanine (ara-G), an active metabolite of nelarabine, enters leukemic cells
through human Equilibrative Nucleoside Transporter 1, and is then phosphorylated to an intracellular active
metabolite ara-G triphosphate (ara-GTP) by both cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine
kinase. Ara-GTP is subsequently incorporated into DNA, thereby inhibiting DNA synthesis.
Methods: In the present study, we developed a novel ara-G-resistant variant (CEM/ara-G) of human T-lymphoblastic
leukemia cell line CCRF-CEM, and elucidated its mechanism of ara-G resistance. The cytotoxicity was measured by
using the growth inhibition assay and the induction of apoptosis. Intracellular triphosphate concentrations were
quantitated by using HPLC. DNA synthesis was evaluated by the incorporation of tritiated thymidine into DNA.
Protein expression levels were determined by using Western blotting.
Results: CEM/ara-G cells were 70-fold more ara-G-resistant than were CEM cells. CEM/ara-G cells were also refractory
to ara-G-mediated apoptosis. The transcript level of human Equilibrative Nucleoside Transporter 1 was lowered, and the
protein levels of deoxycytidine kinase and deoxyguanosine kinase were decreased in CEM/ara-G cells. The subsequent
production of intracellular ara-GTP (21.3 pmol/107 cells) was one-fourth that of CEM cells (83.9 pmol/107 cells) after
incubation for 6 h with 10 μM ara-G. Upon ara-G treatment, ara-G incorporation into nuclear and mitochondrial DNA
resulted in the inhibition of DNA synthesis of both fractions in CEM cells. However, DNA synthesis was not inhibited
in CEM/ara-G cells due to reduced ara-G incorporation into DNA. Mitochondrial DNA-depleted CEM cells, which were
generated by treating CEM cells with ethidium bromide, were as sensitive to ara-G as CEM cells. Anti-apoptotic Bcl-xL
was increased and pro-apoptotic Bax and Bad were reduced in CEM/ara-G cells.
Conclusions: An ara-G-resistant CEM variant was successfully established. The mechanisms of resistance included
reduced drug incorporation into nuclear DNA and antiapoptosis.
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Nucleoside analogs belong to one of the most clinically
useful and frequently used classes of agents for the treat-
ment of hematological malignancies [1-6]. Nelarabine,
2-amino-9-β-D-arabinofuranosyl-6-methoxy-9H-purine,
is a relatively new anticancer agent that targets T-cell ma-
lignancies, including T-cell acute lymphoblastic leukemia
and T-cell lymphoblastic lymphoma [4-6]. The Cancer
and Leukemia Group B conducted a phase 2 study of* Correspondence: tyamauch@u-fukui.ac.jp
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unless otherwise stated.nelarabine for adult patients with relapsed or refractory
T-cell leukemia/lymphoma [7]. Treatment with nelara-
bine resulted in a 41% response rate and a 31% complete
remission rate. Although this clinical outcome is promis-
ing, nelarabine therapy should be further optimized by
an improved understanding of its mechanism of action
and by overcoming drug resistance.
Upon intravenous administration, nelarabine is demethy-
lated to the active compound 9-β-D-arabinofuranosylgua-
nine (ara-G) by adenosine deaminase in the plasma
[4,8-11]. Ara-G is transported into leukemic cells mainly
via nitrobenzylthioinosine-sensitive nucleoside membraneral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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(hENT1) [12]. Ara-G is then phosphorylated to ara-G
monophosphate by cytoplasmic deoxycytidine kinase
(dCK) and mitochondrial deoxyguanosine kinase (dGK)
[9]. This phosphorylation is the rate-limiting step of the
intracellular activation of nelarabine. Ara-G nucleotide is
partly dephosphorylated by cytosolic 5′-nucleotidase II
(cN-II). Ara-G monophosphate is then phosphorylated to
ara-G diphosphate and eventually to ara-G triphosphate
(ara-GTP). Ara-GTP is an intracellular active metabolite,
which is subsequently incorporated into both nuclear and
mitochondrial DNA, thereby terminating DNA elongation.
Thus, incorporation of the drug into DNA is critical for its
cytotoxicity [8-10].
Nelarabine resistance is a major obstacle to improving
response rates, and overcoming this drug resistance
would provide new strategies for optimal nelarabine
administration. In the present study, we established a
novel ara-G-resistant subclone of the human T-cell
lymphoblastic leukemia cell line, CCRF-CEM. Factors
involved in the intracellular activation of ara-G that
might be closely related to ara-G resistance [8-12], in-
cluding hENT1, dCK, dGK, cN-II, and drug incorpor-
ation into DNA, were extensively investigated. Because
ara-G is phosphorylated by cytoplasmic dCK and mito-
chondrial dGK, the contribution of both nuclear and
mitochondrial DNA damage was evaluated. Moreover,
because the induction of apoptosis is the final output of
mechanism of ara-G cytotoxicity, the levels of apoptosis-
related proteins were determined.
Methods
Reagents
Ara-G was purchased from R.I. Chemicals (Orange, CA,
USA) and dissolved in 100% dimethyl sulfoxide. Standard
ara-GTP was provided by GlaxoSmithKline, Japan (Tokyo,
Japan). [5-3H] ara-G (30 Ci/mmol) was purchased from
Moravek Biochemicals, Inc (Brea, CA, USA). Nine-β-D-
arabinofucanosyl-2-fluoroadenine (F-ara-A) and cytarabine
(ara-C) were purchased from Sigma-Aldrich (St Louis,
MO, USA).
Cell culture and development of an ara-G-resistant
subclone
Human T-cell lymphoblastic leukemia CCRF-CEM cells
were cultured in RPMI1640 media supplemented with
10% fetal calf serum. An ara-G-resistant variant, CEM/
ara-G, was established by serial incubation of the cells
with ara-G, followed by limiting dilution for cloning. In
brief, the parental CEM cells were maintained with es-
calating concentrations of ara-G. The initial concentra-
tion (0.2 μM) was one tenth the concentration required
to inhibit 50% growth of CEM cells (IC50). The cultures
were observed daily and allowed to grow. In subsequentpassages, the concentration of ara-G was gradually in-
creased. Passaging was repeated for 10 months. When the
ara-G concentration in the culture media reached 20 μM,
one cell line resistant to ara-G (CEM/ara-G) was cloned by
the limiting dilution method [13].
Drug treatment
Both CEM and CEM/ara-G cells (2 × 106 cells/ml, 10 ml)
were incubated at 37°C with various concentrations of radi-
olabeled or non-labeled ara-G for the time periods indi-
cated. Cells were then washed twice with PBS and
centrifuged (500 × g, 5 min, 4°C) to collect the cell pellet.
Proliferation assay
Growth inhibition effects were determined by the so-
dium 3′-(1-[(phenylamino)-carbonyl-3,4-tetrazolium])-bis
(4-methoxy-6-nitro) benzene sulfonic acid hydrate (XTT)
assay according to the manufacturer’s instructions (Roche,
Indianapolis, IN, USA) with slight modifications [13].
Alternatively, the number of viable cells were quanti-
tated as of the ATP present, which signals the presence
of metabolically active cells, by using The CellTiter-Glo®
Luminescent Cell Viability Assay kit (Promega Corp.,
Madison, WI, USA). Briefly, the cell suspension having
been treated were added to the reagent (1:1, v/v). The
sample was mixed for 2 min for cell lysis, and allowed to
stand for 10 min to stabilize the luminescent signal. The
luminescence intensity of the sample was measured
thereafter. This method was applied to assess the viability
of mitochondrial DNA-depleted ρ0CEM cells.
Measurement of analog triphosphate concentrations in
leukemic cells
Intracellular concentrations of ara-GTP, F-ara-A triphos-
phate (F-ara-ATP), and ara-C triphosphate (ara-CTP) were
determined by using the HPLC assay method that we pre-
viously established [13,14]. Briefly, cells (1 × 106 cells/ml,
10 ml) were incubated for 6 h with 10 μM ara-G, F-ara-A,
or ara-C. The acid-soluble fraction, the nucleotide pool,
was extracted from the cells by the addition of perchloric
acid followed by neutralization. An aliquot of the sample
was subjected to HPLC analysis. Chromatography was per-
formed with the TSK gel DEAE-2 SW column (250 mm
length × 4.6 mm inside diameter; Tosoh, Tokyo, Japan) and
0.06 M Na2HPO4 (pH 6.9) - 20% acetonitrile buffer at a
constant flow rate of 0.7 ml/min. Each analog triphos-
phate concentration was quantitated by its peak area and
expressed as pmol/107 cells.
Western blot analysis
Protein levels of dCK, dGK, caspase-3, caspase-9, Bcl2,
Bcl-xL, Bax, Bad, Bid, Bim, AKT, and p-AKT were deter-
mined by using standard western blotting techniques
[13]. Mouse monoclonal anti-dCK was developed in the
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Medicine [13]. Rabbit polyclonal anti-dGK antibody
(Abgent, San Diego, CA, USA), rabbit polyclonal anti-
caspase-3 (Cell Signaling Technology, Beverly, MA,
USA), rabbit polyclonal anti-caspase-9 (Cell Signaling
Technology), rabbit polyclonal anti-Bcl-2 (Cell Signal-
ing Technology), rabbit polyclonal anti-Bcl-xL (Cell
Signaling Technology), rabbit polyclonal anti-Bax (Cell
Signaling Technology), rabbit polyclonal anti-Bad (Cell Sig-
naling Technology), rabbit polyclonal anti-Bid (Cell Signal-
ing Technology), rabbit polyclonal anti-Bim (Cell Signaling
Technology), rabbit polyclonal anti-AKT (Cell Signal-
ing Technology), rabbit polyclonal anti-P-AKT (Santa
Cruz Biotechnology, Inc. Dallas, TX, USA), and anti-
actin antibodies (Sigma-Aldrich) were used as primary
antibodies [13].
Determination of hENT1 and cN-II transcripts
To evaluate mRNA levels of hENT1 (accession: NM_
001078177) and cN-II (accession: NM_012229), real-time
RT-PCR was performed by using the ABI Prism 7900
sequence detection system (Applied Biosystems, Foster
City, CA, USA) as previously described [13,15]. Primers
for hENT1 and cN-II were purchased from Applied Bio-
systems. The relative quantification method was used.
The expression level of hENT1 or cN-II was normalized
using β-Actin as a house-keeping gene in each cell line.
The final value was expressed as the ratio of the expres-
sion level of hENT1 or cN-II of CEM/ara-G cells to that
of CEM cells (the expression level of hENT1 or cN-II of
CEM cells was set as 1).
Calculation of ara-G incorporation into both nuclear and
mitochondrial DNA
Both nuclear and mitochondrial DNA fractions were
isolated from cells after incubation with tritiated ara-G
for the indicated time periods at 37°C. For nuclear
DNA isolation, the acid-insoluble fraction (obtained
as described above) was used. To solubilize RNA, the
acid-insoluble fraction was resuspended in 100 μl of 0.4
N KOH and kept at room temperature for 4 h. The
sample was then mixed with 100 μl of 5% perchloric
acid and 20 μl of 4 N HCl, followed by centrifugation
(15,000 × g, 30 sec, 4°C). After removal of the super-
natant (RNA), the precipitate was mixed with 100 μl of
5% perchloric acid and heated at 92°C for 20 min to
solubilize DNA. After centrifugation (15,000 × g, 30 sec,
4°C), the supernatant was isolated as DNA, and the pre-
cipitate (protein) was discarded [16]. The mitochondrial
fraction was extracted by using the Qproteome Mito-
chondria Isolation Kit (Qiagen, Valencia, CA, USA) ac-
cording to the manufacturer’s instructions. Radioactivity
was determined in both fractions by using a liquid scintil-
lation counter.Evaluation of nuclear and mitochondrial DNA synthesis
The inhibition of DNA synthesis by ara-G was evaluated
by assessing the incorporation of tritiated thymidine
into DNA [17]. Cells (2 × 106 cells) were pre-incubated
with or without 10 μM ara-G for 3 h, followed by
washing in fresh media and subsequent incubation with
tritiated thymidine for 4 h. The nuclear and mitochon-
drial DNA fractions were extracted as described above
and evaluated for radioactivity by using a liquid scintil-
lation counter.
Quantitation of apoptotic cell death
To evaluate cytotoxicity, apoptotic cell death was deter-
mined by staining for phosphatidylserine externalization
by using annexin V (Roche Applied Science, Indianapo-
lis, IN, USA) or for the sub-G1 cell cycle population by
using propidium iodide (Beckman Coulter, Fullerton,
CA, USA) and performing flow cytometry 72 h after
treatment [18]. To confirm the induction of mitochon-
drial apoptosis, the cleavage of caspase-3 and caspase-9
was detected by western blotting as described above.
Derivation of mitochondrial DNA-depleted cells
(ρ0CEM cells)
CEM cells were cultured in the presence of 100 ng/ml
ethidium bromide to inhibit mitochondrial DNA replica-
tion for more than 20 generations (almost 1 month)
[19]. ρ0 cells were derived and maintained in the pres-
ence of 50 mg/ml uridine. The total cellular enzyme ac-
tivity of cytochrome c oxidase, subunits of which are
encoded by mitochondrial DNA, was tested by using the
Mitochondrial Activity Assay Kit (BioChain, Institute,
Inc., Hayward, CA, USA) according to the manufacturer’s
instructions.
Statistical analyses
All statistical analyses were performed with Microsoft
Excel 2007 (Microsoft Corporation, Redmond, WA, USA).
All graphs were generated using GraphPad Prism (version
5.0; GraphPad Software, San Diego, CA, USA).
Results
Establishment of ara-G-resistant CEM (CEM/ara-G) cells
The XTT proliferation assay demonstrated that CEM/
ara-G cells were 70-fold more resistant to ara-G than
CEM cells (Figure 1a, Table 1). Because growth rates
for both cell lines were similar (Figure 1b) with a
doubling time of 22.0 h for CEM cells and 21.4 h for
CEM/ara-G cells, the resistance to this S-phase-specific
drug was not attributable to cycling speed. The intra-
cellular ara-GTP production (21.3 pmol/107 cells) was
reduced by 1/4 in CEM/ara-G cells compared with that
(83.9 pmol/107 cells) in CEM cells (Figure 1c). CEM/
ara-G cells were also resistant to ara-G-induced apoptosis
Figure 1 Establishment of ara-G-resistant CEM variant, CEM/ara-G. (a) The growth inhibition curve. Cells were incubated with various
concentrations of ara-G for 72 h, and the IC50 was then determined by using the XTT assay. (b) Doubling time for CEM cells and CEM/ara-G cells.
(c) Intracellular ara-GTP concentrations. CEM cells and CEM/ara-G cells were incubated for 6 h with 10 μM ara-G, followed by an extraction of the
nucleotide pool and subsequent measurement of ara-GTP by using HPLC. *P = 0.0006 determined by unpaired T test. (d) Apoptotic cell death
induced by ara-G. CEM cells and CEM/ara-G cells were incubated with 10 μM ara-G for 72 h, followed by the evaluation of annexin V positivity by
flow cytometry. *P = 0.002 determined by unpaired T test. The values shown are the mean ± SD of at least three independent experiments.
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demonstrated in CEM cells treated with ara-G, sug-
gesting that mitochondria-mediated apoptosis was in-
duced by ara-G (Figure 2). In contrast, caspase cleavage
was not induced in CEM/ara-G cells treated with 100 μMTable 1 Drug sensitivities of CEM and CEM/ara-G cells
Drug IC50 (μM)
CEM CEM/ara-G RR
Ara-G 2.6 180 (70)
F-ara-A 0.10 4.80 (48)
Ara-C 0.15 0.75 (5)
CEM and CEM/ara-G cells were incubated for 72 h with various concentrations
of ara-G, ara-C, or F-ara-A. The IC50 was then determined by using the XTT
assay. The number in the parenthesis is the relative resistance (RR), which was
obtained by dividing the IC50 value of CEM/ara-G cells by that of CEM cells.ara-G (Figure 2). Thus, the ara-G-resistant CEM variant,
CEM/ara-G, was successfully established, which yielded
a small amount of ara-GTP and was consequently
more resistant to ara-G-induced growth inhibition and
apoptosis.Cross-resistance in CEM/ara-G cells
The XTT assay also revealed that CEM/ara-G cells
were cross-resistant to similar nucleoside analogs, ara-C
and fludarabine nucleoside F-ara-A (Table 1). Intra-
cellular analog triphosphate production was also de-
termined. CEM/ara-G cells yielded lower amounts of
both ara-CTP and F-ara-ATP than CEM cells (Figure 3).
Ara-CTP and F-ara-ATP were 3,400 ± 400 pmol/107 cells
and 190 ± 36 pmol/107 cells in CEM cells, and 363 ± 84
pmol/107 cells and 29 ± 13 pmol/107 cells in CEM/ara-G
Figure 2 Induction of apoptosis. CEM cells and CEM/ara-G cells
were incubated for 72 h with 10 or 100 μM ara-G, followed by the
examination of caspase cleavage.
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F-ara-A in CEM/ara-G cells was associated with the de-
creased production of intracellular analog triphosphates.
Evaluation of factors (hENT1, dCK, dGK, and cN-II) essential
for intracellular ara-GTP production
The mechanism of resistance to nucleoside analogs
is usually associated with impaired production of
intracellular analog triphosphate [20,21]. The level of
hENT1 transcript was decreased in CEM/ara-G cells
(Figure 4a), suggesting a decreased cellular uptake of
the nucleoside analog. Both dCK and dGK protein
expression was also decreased in CEM/ara-G cells
(Figure 4b). Transcript levels of the degrading en-
zyme cN-II were comparable between CEM cells and
CEM/ara-G cells (Figure 4c). Thus, the cellular uptakeFigure 3 Intracellular analog triphosphate production. CEM cells and C
(b), followed by extraction of the nucleotide pool and measurement of int
for CEM versus CEM/ara-G for ara-CTP production by unpaired T test (a). P =
T test (b). The values shown are the means ± SD of at least three independand intracellular phosphorylation of ara-G were im-
paired in CEM/ara-G cells, which led to decreased ara-
GTP production.
Inhibition of DNA synthesis by the incorporation of ara-G
into DNA
The critical cytotoxic event of a nucleoside analog is
incorporation of the intracellular analog triphosphate
into nuclear DNA, thereby terminating DNA synthe-
sis [16,22,23]. The uptake of thymidine into DNA
was evaluated in the presence or absence of ara-G in
both cell lines. Pre-incubation with 10 μM ara-G,
which is a concentration that is cytotoxic to CEM
cells but not to CEM/ara-G cells, inhibited the in-
corporation of tritiated thymidine into both the nu-
clear and mitochondrial DNA fractions in CEM cells
(Figure 5a, b). However, thymidine incorporation into
DNA was not inhibited in either fraction of CEM/
ara-G cells (Figure 5a, b). Along with DNA synthesis
inhibition, ara-G incorporation into DNA was evalu-
ated in the nuclear and mitochondrial fractions of
both cell lines. After treatment with 10 μM ara-G, the
amounts of ara-G incorporated into the DNA of both
fractions of CEM/ara-G cells were reduced compared
with those of CEM cells (Figure 5c). The reduction was
comparable between the nuclear DNA and mitochon-
drial DNA fractions of CEM/ara-G cells (Figure 5c).
The reduced incorporation of ara-G might correspond
to the failed inhibition of thymidine incorporation
(Figure 5a, b). Thus, CEM/ara-G cells were refractory
to ara-G-mediated DNA synthesis inhibition of both
nuclear and mitochondrial DNA fractions due to the
reduced ara-G incorporation into DNA. The reduced
ara-G incorporation might be attributable to the de-
creased production of intracellular ara-GTP in CEM/
ara-G cells.EM/ara-G cells were incubated for 6 h with 10 μM ara-C (a) or F-ara-A
racellular analog triphosphate concentrations by using HPLC. P = 0.026
0.001 for CEM versus CEM/ara-G for F-ara-ATP production by unpaired
ent experiments.
Figure 4 Factors associated with the intracellular activation of ara-G in CEM cells and CEM/ara-G cells. (a) Real-time RT-PCR was performed to
determine the transcript level of hENT1. (b) Western blot analysis of dCK and dGK. (c) Real-time RT-PCR was performed to determine the transcript level
of cN-II.
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(ρ0CEM cells)
The role of the mitochondrial DNA damage in ara-G
cytotoxicity was further evaluated. If mitochondrial
DNA is a target of ara-G cytotoxicity, it was hypoth-
esized that mitochondrial DNA-depleted cells would
become resistant to ara-G. CEM cells were cultured in
the presence of ethidium bromide to generate a mito-
chondrial DNA-depleted derivative (ρ0CEM). The oxi-
dase activity of cytochrome c, which is formed from
subunits encoded by mitochondrial DNA, was almost ab-
sent in ρ0CEM cells (Figure 6a), indicating the successful
depletion of mitochondrial DNA. The ATP-based prolif-
eration assay revealed that the IC50 values were compar-
able between CEM cells and ρ0CEM cells (Table 2). The
induction of apoptotic cell death was also evaluated in
these cell lines. Intact mitochondrial function is not es-
sential for inducing apoptosis because most ρ0cell lines
undergo apoptosis in response to death signals and
cytotoxic agents as efficiently as their parental cell linesFigure 5 DNA synthesis inhibition by ara-G. CEM cells and CEM/ara-G c
4-h incubation with tritiated thymidine. Nuclear (a) and mitochondrial (b)
Percentages are the ratio of the values of thymidine incorporation into th
those without ara-G pre-incubation. P = 0.0003 for CEM versus CEM/ara-G
CEM versus CEM/ara-G for mitochondrial DNA synthesis inhibition by unp
radio-labeled ara-G for 6 h, followed by extraction of nuclear and mitochon
The relative ara-G incorporation is the ratio of the value of ara-G incorporation
The values shown are the means ± SD of at least three independent experim[24-27]. Ara-G induced apoptosis equally in CEM cells and
ρ0CEM cells, regardless of the ara-G concentration
(Figure 6b, c). These results suggested that ara-G-induced
mitochondrial DNA damage was unlikely to greatly con-
tribute to ara-G cytotoxicity.
Apoptosis-related proteins
Apoptosis- and survival-related proteins were compared
between CEM cells and CEM/ara-G cells (Figure 7). Anti-
apoptotic Bcl-xL was augmented and pro-apoptotic Bax
and Bad were reduced in CEM/ara-G cells, suggesting
refractoriness to ara-G-induced apoptosis. The levels of
mitochondrial apoptosis-related proteins, including Bcl-2,
Bcl-xL, Bax, Bad, Bid, and Bim, were not altered in ρ0CEM
cells. Pro-survival AKT and P-AKT levels were equivalent
among CEM cells, CEM/ara-G cells, and ρ0CEM cells [28].
Discussion
In the present study, we developed a new cell line vari-
ant of the T lymphoblastic leukemia CCRF-CEM cellells were incubated with or without 10 μM ara-G for 3 h, followed by a
DNA fractions were isolated and subjected to scintillation counting.
e DNA of the cells that had been pre-treated with ara-G relative to
for nuclear DNA synthesis inhibition by unpaired T test. P = 0.045 for
aired T test. (c) CEM and CEM/ara-G cells were incubated with 10 μM
drial DNA. Then, the samples were subjected to scintillation counting.
into the DNA of CEM/ara-G cells to that of CEM cells. n.s., not significant.
ents.
Figure 6 Ara-G cytotoxicity against mitochondrial DNA-depleted CEM (ρ0CEM) cells. (a) Determination of cytochrome c oxidase activity in
ρ0CEM cells. The activity was completely suppressed in mitochondrial DNA-depleted variant cell line ρ0CEM as compared with CEM cells. (b, c) CEM
cells and ρ0CEM cells were treated with 10 μM (b) or 100 μM (c) ara-G for 48 h. Sub-G1 induction was calculated by using flow cytometry. The values
shown are the means ± SD of at least three independent experiments. The difference in the values between CEM cells and ρ0CEM cells was
not significant for either concentration (P = 0.28 for 10 μM ara-G (b), P = 0.40 for 100 μM ara-G (c), unpaired T test).
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of nelarabine (Figures 1 and 2, Table 1), and investi-
gated its mechanism of drug resistance. Reduced trans-
porter hENT1 transcript level and decreased dCK and
dGK protein levels (Figure 4) resulted in decreased ara-
GTP production (Figure 1) in CEM/ara-G cells. The
subsequent incorporation of ara-G into nuclear and
mitochondrial DNA was reduced (Figure 5), and unable
to inhibit DNA synthesis in both fractions of CEM/
ara-G cells (Figure 5). Importantly, the cytotoxic effect of
ara-G was almost unchanged on CEM cells that were de-
pleted of mitochondrial DNA (Figure 6, Table 2), suggest-
ing that mitochondrial DNA damage was unlikely to
contribute greatly to ara-G cytotoxicity. Thus, the re-
duced triphosphate production (Figure 1) and the subse-
quent reduction of drug incorporation into nuclear DNA
(Figure 5) were closely associated with the develop-
ment of ara-G resistance in CEM/ara-G cells. The anti-
apoptotic nature was also related to the drug resistance in
this cell line (Figure 7).
Previously, 3 independent studies investigated the
mechanisms of ara-G resistance in leukemic cell lines.
Shewach et al. first developed an ara-G-resistant leukemic
clone from T lymphoblastic leukemia MOLT-4 cells and
demonstrated decreased production of intracellular ara-
GTP [29]. However, they did not determine the mecha-
nisms for the reduced ara-GTP production. Curbo et al.





CEM cells and mitochondria-depleted ρ0CEM cells were incubated for 72 h
with various concentrations of ara-G. The IC50 was then determined by using
the ATP-based assay.132-fold and 260-fold more ara-G resistant than CEM
[30]. They demonstrated a decrease in ara-G incorpor-
ation into mitochondrial DNA and loss of dCK activity.
However, they showed that the drug incorporation into
mitochondrial DNA was not associated with the acuteFigure 7 Protein levels of Bcl-2, Bcl-xL, Bax, Bad, Bid, Bim EL
(extra long), AKT, and phospho-AKT. These levels were determined
by Western blotting in CEM cells, CEM/ara-G cells, and ρ0CEM cells.
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Their latest study further demonstrated that the depletion
of mitochondria DNA does not attenuate the cytotoxicity
of ara-G in MOLT-4 cells [32]. They concluded that the
loss of dCK activity is the critical factor responsible for
ara-G resistance. Our study demonstrated that ara-G
inhibited both nuclear and mitochondrial DNA synthesis
in CEM cells (Figure 5). However, the result showing that
ρ0CEM cells were similarly sensitive to ara-G (Figure 6)
suggests that the critical event should be the inhibition of
nuclear DNA synthesis not mitochondrial DNA damage.
Lotfi et al. developed 2 ara-G-resistant MOLT-4 variants
that were 108-fold and 184-fold more ara-G resistant than
MOLT-4 [33]. They showed that dGK deficiency was the
most prominent change in these cells and that a dCK de-
fect was associated with increased ara-G resistance [33].
They further identified increases in Bcl-xL in these ara-G-
resistant clones [34]. The alteration of the kinases and
anti-apoptotic Bcl-xL indicate a possible contribution of
these factors to ara-G resistance, which is consistent with
our present findings. Nevertheless, apart from these re-
ports, we clearly showed all of the successive changes in
the transporter hENT1, kinases (dCK and dGK), ara-GTP
production, ara-G incorporation into nuclear and mito-
chondrial DNA, inhibition of DNA synthesis, and induc-
tion of mitochondria-mediated apoptosis. Thus, unlike
previous studies, the present study was comprehensive
and systematic in investigating the mechanism of resist-
ance to ara-G in leukemic cells.
CEM/ara-G cells demonstrated cross-resistance to
F-ara-A and ara-C. However, the resistance to the purine
analog F-ara-A was much greater than that to the pyrimi-
dine analog ara-C (Table 1). Because F-ara-A and ara-C
share an identical pathway for their intracellular activation,
the difference in resistance might be due to a structural
difference between the 2 agents, but this possibility was
not investigated in detail here. Nevertheless, one strategy
to overcome ara-G resistance may be a high-dose ara-C
therapy that can achieve 50-fold higher plasma ara-C con-
centrations than regular-dose ara-C, which would surpass
the level of cross-resistance to ara-C [35,36].
Conclusions
An ara-G-resistant CEM variant was successfully estab-
lished. The mechanism of resistance included reduced drug
incorporation into nuclear DNA and antiapoptosis.
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